Who is the manufacturer of venetoclax/venetoclax tablets?

Venetoclax/Venetoclax (Venetoclax), trade names Venclexta and Venclyxto, is an innovative drug that is widely used to treat adult chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). The drug is developed and manufactured by AbbVie and marketed by AbbVie and Genentech. Venaclat is the first BCL-2 inhibitor officially approved by the U.S. Food and Drug Administration (FDA). It can be used in conjunction with a variety of other drugs such as azacitidine and decitabine.

The mechanism of action of venetoclax is that it can specifically bind to a protein calledBcl-2. This protein is highly expressed in cancer cells of chronic lymphocytic leukemia and plays a role in extending the survival time of cancer cells in the body and increasing their resistance to anti-cancer drugs. Venetoclax blocks the function of Bcl-2 and induces cancer cells to undergo apoptosis, thereby effectively slowing down the progression of the disease. It is worth mentioning that venetoclax can begin to exert its effect in a very short period of time, perhaps even within 24 hours, and rapidly induce CLL cell apoptosis, but this may also lead to the risk of tumor lysis syndrome.

Some common side effects that patients may experience while using venetoclax include a decrease in neutrophil count, diarrhea, nausea, anemia, upper respiratory tract infection, and fatigue. Although venetoclax has shown remarkable efficacy in treating the above-mentioned diseases, patients still need to remain highly vigilant about possible side effects during medication and take corresponding countermeasures in a timely manner when necessary.